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Abstract  
 
Multi-ionisable compounds, such as dicarboxylic acids, offer the possibility of forming 
salts of drugs with multiple stoichiometries. Attempts to crystallise ciprofloxacin, a 
poorly water soluble, amphoteric molecule with succinic acid (S) resulted in isolation of 
ciprofloxacin hemisuccinate (1:1) trihydrate (CHS-I) and ciprofloxacin succinate (2:1) 
tetrahydrate (CS-I). Anhydrous ciprofloxacin hemisuccinate (CHS-II) and anhydrous 
ciprofloxacin succinate (CS-II) were also obtained. It was also possible to obtain 
stoichiometrically equivalent amorphous salt forms, CHS-III and CS-III, by spray drying 
and milling, respectively, of the drug and acid. Anhydrous CHS and CS had melting 
points at ~215 and ~228 °C, while the glass transition temperatures of CHS-III and CS-III 
were ~101 and ~79 °C, respectively. Dynamic solubility studies revealed the metastable 
nature of CS-I in aqueous media, resulting in a transformation of CS-I to a mix of CHS-I 
and ciprofloxacin 1:3.7 hydrate, consistent with the phase diagram. CS-III was observed 
to dissolve non-congruently leading to high and sustainable drug solution concentrations 
in water at 25 and 37 ºC, with the ciprofloxacin concentration of 58.8±1.18 mg/ml after 1 
hour of the experiment at 37 ºC. This work shows that crystalline salts with multiple 
stoichiometries and amorphous salts have diverse pharmaceutically-relevant properties, 
including molecular, solid state and solubility characteristics.     
 
 
 
Key words: ciprofloxacin, succinic acid, solubility, ternary phase diagram, single crystal 
X-ray, dynamic vapour sorption, morphology. 
 
 2
1. Introduction 
Ciprofloxacin (C), 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-quinoline-3-
carboxylic acid (Fig. 1), is a widely used second generation fluoroquinolone antibacterial 
compound for the treatment of bacterial infections of the lower respiratory tract and skin 
tissue.  
 
 
Figure 1. Chemical structure of ciprofloxacin.   
 
C is a class IV of the Biopharmaceutics Classification System drug1, 
predominantly absorbed in the proximal part of the gastrointestinal tract (GIT).2 The 
aqueous solubility of C is pH-dependent, due to the presence of the carboxylic and NH 
groups of piperazine, with the zwiterionic and unionised forms being dominant at neutral 
pH.3 Since solubility is one of the properties which directly impacts on bioavailability of 
an active pharmaceutical ingredient (API), salt formation using suitable counterions is an 
approach often employed to improve the aqueous solubility of drugs. Indeed, C is 
commercially available as a hydrochloride 1.4-hydrated salt, the structure of which has 
been described by Turel and Golobic.4 However, hydrochloride salts often suffer from a 
decreased solubility in the stomach due to a common ion effect.5 Taking the above into 
consideration, alternative forms of C, which do not contain the chloride counterion and 
N
NH
F
N
O O
OH
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exhibit high solubility at the pH of the absorption site (the upper part of the GIT) might 
therefore be useful.  
Preparation of C salts with organic acids such as citric, tartaric and malonic acid 
has previously been presented.6 Recently, we reported on the ability of another 
amphoteric molecule, salbutamol, to form a salt with succinic acid or a cocrystal of 
salbutamol adipate salt with adipic acid.7 All of the above examples of counterions 
include organic acids with more than one carboxylic group, potentially presenting the 
possibility of the formation of salts with multiple stoichiometries. While, in theory, it is 
possible to predict whether multiple stoichiometries are likely to form, based on the 
chemical structure of the drug and counterion, it is not yet possible to predict if salts with 
different stoichiometries will crystallise.8 Mono- and bis-hydrochloride salts of 
GSK159797 have been reported.9 Tamoxifen has been isolated as a 1:1 (molar ratio) 
anhydrous citrate salt as well as a sesquihydrate with the 2:1 molar ratio of the drug to the 
counterion.10 Multiple stoichiometries of succinic salts of a pleuromutilin derivative have 
also been characterised.11 The ciprofloxacin salts obtained by Reddy et al. were of 1:1 
drug:acid stoichiometry only.6 Succinic acid, due to its pKa values close to each other 
(4.21 and 5.64)12 and thus greater likelihood of di-anion formation, may be a better 
counterion to study the potential of ciprofloxacin (pKa values of 6.09 and 8.74)13 to form 
salts with multiple stoichiometries.  
Guerrieri et al. stated that amorphous salts might provide an opportunity to 
enhance dissolution behaviour in biological fluids due to a higher solubility of the ionised 
drug in comparison to the nonionised form and the higher apparent solubility of the 
amorphous form.14 Although amorphous forms of salts are known, the published studies 
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have primarily concentrated on investigations of the solid state properties, including the 
work of Guerrieri et al. on procaine salts.14 Examples include the work of Tong et al. on 
correlating the glass transition temperature (Tg) of amorphous alkali metal salts of 
indomethacin with the size/charge ratio of the counterion.15 In another study the Tgs, 
crystallisation tendency and moisture sorption behaviour of amorphous salts of 
nicardipine or propranolol were systematically investigated however no apparent trends 
between these parameters and the counterions used were evident.16 Sonje et al., in 
addition to an extensive account on the Tgs, fragility and devitrification tendency of 
amorphous salts of atorvastatin manufactured by spray drying, concluded that greater 
dissolution rates, in comparison to the crystalline counterparts, were obtained using 
amorphous salts of magnesium and calcium, but not sodium.17 Hasa et al. obtained a 
rapidly and highly absorbed amorphous salt, vinpocetine citrate, by neat co-grinding a 
mix of the drug and the acid in the presence of amorphous polymer, crospovidone.18 
Consequently, the aim of this work was to explore the possibility of crystalline 
ciprofloxacin salt formation with succinic acid with an emphasis on screening whether 
this drug molecule can form salts with multiple stoichiometries. Also, considering that 
only very limited information on pharmaceutically-relevant properties of amorphous salts 
can be found, to manufacture the amorphous counterparts of any ciprofloxacin succinate 
form(s) and compare the physicochemical properties of the various forms.  
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2. Materials and methods  
2.1. Materials  
Ciprofloxacin (anhydrous, Fluka, China) later referred to as C, succinic acid (S) 
(Aldrich, USA), water (Millipore Elix 3 UK), ethanol (Corcoran Chemicals, Ireland), 
potassium bromide, sodium chloride, sodium hydroxide and triethylamine (Sigma-
Aldrich, Germany), 85% phosphoric acid, 37% hydrochloric acid, sodium dihydrogen 
phosphate dihydrate and Karl-Fischer universal reagent (Riedel de Haen, Germany), 
HPLC acetonitrile and HPLC methanol (Fischer Scientific, UK).  
2.2. Methods 
2.2.1. Production of salts 
2.2.1.1. Preparation of crystalline bulk materials  
Ciprofloxacin hemisuccinate (1:1) trihydrate (CHS-I) was crystallised by cooling 
a 80 ml aqueous solution of 3 mmol anhydrous ciprofloxacin (C) and 3 mmol succinic 
acid (S) from 70 °C to 4 °C at a rate of 1 °C/min. 
Ciprofloxacin succinate (2:1) tetrahydrate (CS-I) was crystallised by cooling a 
50% v/v ethanolic solution (50% ethanol/50% water v/v) containing C and S in the 1:1 
molar ratio from 70 °C to 4 °C (1 °C/min). In order to avoid conversion of C to C-I 
(ciprofloxacin hydrate), 1.5 mmol S was first dissolved in 20 ml pure water and then 
heated to 70 °C. 1.5 mmol C was dissolved in the warm solution of S and the required 
amount of warm ethanol (at 70 °C) was added to form the 50% v/v ethanolic solution. 
Anhydrous ciprofloxacin hemisuccinate (CHS-II) was crystallised by evaporation 
of a 1:1 (molar ratio) aqueous solution of C and S under reduced pressure (-80 mbar) at 
70 °C using a rotary evaporator (Büchi Rotavapor R-210, Flawil, Switzerland). 
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Anhydrous ciprofloxacin succinate (CS-II) was obtained by tray drying of CS-I in 
an oven (Memert, Germany) for 6 hours at 70 ˚C, until the mass loss recorded by 
thermogravimetric analysis (TGA) was lower than 1% w/w in the temperature range of 
25-150 ˚C at a heating rate of 10 ˚C/min.  
2.2.1.2. Preparation of single crystals  
 In order to grow the crystals of CHS-I and CS-I of sufficient size and quality for 
the single crystal X-ray diffraction analysis, the liquid diffusion method was used.19 An 
aqueous solution of S and C (1:1 molar ratio), saturated at room temperature, was 
covered in a glass vial with a layer of pure ethanol. The ethanol layer was applied very 
gently to form two layers of liquids. Equal volumes of the liquids were used. Crystals of 
both phases grew at the boundary layer of the ethanol and aqueous solution. 
2.2.1.3 Spray drying 
The feed solutions were prepared by dissolving C and S in the 1:1 molar ratio in 
water and spray dried using a Büchi B-290 Mini Spray dryer (Flawil, Switzerland). The 
drying gas (compressed, dehumidified air for open mode and nitrogen for closed mode) 
pressure was 6 bar at 4 cm gas flow (rotameter setting), equivalent to 473 norm litres per 
hour (NL/h) of gas flow in normal conditions (p=1013.25 mbar and T=273.15 K).20 A 
standard atomization nozzle with a 1.5 mm cap and 0.7 mm tip was employed for 
processing. The nozzle pressure drop was measured to be 0.41 bar. The pump speed was 
set to 30% (9-10 ml/min) and the aspirator was operated at 100%. The Inert Loop Büchi 
B-295 was used to spray dry in the closed mode configuration and its temperature was set 
to 20 °C. The solution feed concentration used was 1%, 1.5% or 2% (w/v) and the inlet 
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temperature 80, 120, 140, 160, 170 or 180 °C resulting in an outlet temperature ranging 
from 38 to 98 °C depending on the combination of process parameters used. 
2.2.1.4 Milling 
Amorphous CS-III was prepared by dry milling a physical mix of C and S (2:1 
molar ratio) at room temperature using a planetary ball mill PM 100 (Retsch, Haan, 
Germany) at 600 rpm speed. The powder to ball weight ratio was 1:48 as 2 g of powder 
was loaded to the stainless steel milling container which had a volume of 50 ml and three 
stainless steel balls (20 mm in diameter, 32 g each) were used for all milling experiments.  
2.2.2. Single crystal X-ray diffraction (SCXRD)  
Crystal data were collected using an Agilent Technologies (former Oxford 
Diffraction) SuperNova A diffractometer fitted with an Atlas detector. CHS-I was 
measured with Cu-Kα (1.54184 Å), CS-I with Mo- Kα (0.71073 Å). A complete (CS-I) 
or fivefold redundant (CHS-I) dataset was collected, assuming that the Friedel pairs are 
not equivalent. An analytical absorption correction based on the shape of the crystal was 
performed.21 The structures were solved by direct methods using SHELXS-9722 and 
refined by full matrix least-squares on F2 for all data using SHELXL-97.22 Hydrogen 
atoms were added at calculated positions and refined using a riding model. Their 
isotropic temperature factors were fixed to 1.2 times (1.5 times for methyl groups) the 
equivalent isotropic displacement parameters of the carbon atom the H-atom is attached 
to. Anisotropic thermal displacement parameters were used for all non-hydrogen atoms. 
To evaluate the data, Mercury 2.2 software was used.23  
2.2.3. Powder X-ray diffraction (PXRD) 
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Powder XRD analysis was conducted using a Rigaku MiniflexII Desktop X-ray 
diffractometer (Tokyo, Japan) with Haskris cooling unit (Grove Village, IL, USA). The 
tube output voltage used was 30 kV and tube output current was 15 mA. A Cu-tube with 
Ni-filter suppressing Kβ radiation was used. Measurements were taken from 5 to 40 on 
the 2 theta scale at a step size of 0.05˚ per second in each case.24 Scans were performed at 
room temperature. All PXRD measurements were performed in duplicate. 
2.2.3.1. Calculation of crystallite shapes 
To calculate the theoretical crystallite shapes of the materials, PXRD patterns 
were analysed using Peak Search software (Rigaku, Japan).  Baseline noise was corrected 
and relative intensities of Bragg peaks were calculated. Collected data was analysed using 
VESTA software (ver. 3.1.1)25 as described by Izumi and Momma.26 
2.2.4. Differential scanning calorimetry (DSC) 
DSC experiments were performed using a Mettler Toledo DSC 821e 
(Schwerzenbach, Switzerland) with a refrigerated cooling system LabPlant RP-100 
(Filey, UK). Nitrogen was used as the purge gas. Aluminium sample holders (40 µL) 
were sealed with a lid and pierced to provide three vent holes. Sample volume was 
sufficient to provide proper contact between the powder and the bottom of the pan, and 
sample weight was ≥5 mg. DSC measurements were carried out at a heating/cooling rate 
of 10 ˚C/min.27 The unit was calibrated with indium and zinc standards. All DSC 
measurements were performed in triplicate. All DSC results presented are those obtained 
at 10 ˚C/min unless stated otherwise.  
2.2.4.1. Temperature modulated differential scanning calorimetry (MT-DSC 
StepScan
TM
)
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 A PerkinElmer Diamond DSC unit (Waltham, MA, USA) with HyperDSC was 
implemented to detect glass transition temperatures of amorphous systems.28 The unit 
was refrigerated using an ULSP B.V. 130 cooling system (Ede, Netherlands) and 
operated under a nitrogen flow of 40 ml/min. The gas flow was controlled using a 
PerkinElmer Thermal Analysis Gas Station (TAGS). Samples were heated at 5˚C/min in 
2 ˚C steps. Between each of the dynamic steps a 1 minute isothermal step was applied. 
The area algorithm was applied to calculate the specific heat of glass transition from the 
enthalpy flow. A baseline run was performed for each sample to minimise sample holder 
mass error. Samples were tested in 18 µL aluminium holders sealed with pierced lid to 
provide three vent holes. Sample volume was sufficient to provide proper contact 
between powder and a pan bottom, never less than 5 mg. The unit was calibrated with 
indium and zinc standards. Presented results are the average of triplicate analyses. 
2.2.4.2 High speed DSC (HSDSC) 
HSDSC measurements were carried out using a PerkinElmer Diamond DSC unit 
with HyperDSC described as above. Heating rates of 10, 50, 100, 200, 300, 400 and 
500 °C/min were used with nitrogen (10 ºC/min, 40 ml/min) or helium (other heating 
rates, 60 ml/min) as the purge gas. The samples were prepared as explained in Section 
2.2.4.1. Presented results are the average of triplicate analyses. 
2.2.5. Thermogravimetric analysis (TGA) 
TGA was performed using a Mettler TG 50 (Schwerzenbach, Switzerland) 
module linked to a Mettler MT5 balance. Samples were placed into open aluminium pans 
(5-12 mg). A heating rate of 10 ˚C/min was implemented in all measurements.27 Analysis 
was carried out in the furnace under nitrogen purge and monitored by Mettler Toledo 
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STARe software (version 6.10) with a Windows NT operating system. All TGA 
measurements were performed in triplicate. 
2.2.6. Karl Fischer (KF) titrimetry 
0.5 g of sample was dissolved in pre-titrated 50 ml of methanol. Metrohm 841 
Titrando (Herisau, Switzerland) was used for titration and the unit was calibrated with 20 
µl of water.29 Presented results are the average of triplicate analyses. 
2.2.7. Solid state Fourier transform infrared spectroscopy (FTIR) 
Infrared spectra were recorded on a Nicolet Magna IR 560 E.S.P. spectrometer 
(Madison, WI, USA) equipped with a MCT/A detector, working under Omnic software 
version 4.1. A spectral range of 650-4000 cm-1, resolution 2 cm-1 and accumulation of 64 
scans were used in order to obtain good quality spectra. A KBr disk method was used 
with a 0.5-1% sample loading. KBr disks were prepared by direct compression under 8 
bar pressure for 1 minute.30 All FTIR measurements were performed in duplicate. The 
sample preparation did not affect the spectra, as confirmed with an attenuated total 
reflectance (ATR) spectrometer (data not shown).  
2.2.9. Gas chromatography – mass spectrometry (GC-MS) 
A known weight of each sample was placed in a headspace vial to which 1 ml of 
deionised water was added. The vials were sealed. The vials were then heated and 
agitated at 80 ˚C for 10 minutes in a headspace auto-sampler where the volatile organics 
in the samples were driven into the headspace of the vial (the air above the sample). 1 ml 
of the headspace gas was then extracted by syringe from the vial and injected onto the 
GC-MS Varian Saturn 220 (CA, USA). Ethanol eluted at 8.1 minutes. The column used 
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for the analysis was a WCOT fused Silica 60 m x 0.32 mm ID coating CP-SELECT 624 
CB, df=1.8 µm. GC-MS measurements were performed in triplicate. 
2.2.10. Dynamic vapour sorption (DVS) 
Vapour sorption experiments were performed on a DVS Advantage-1 automated 
gravimetric vapour sorption analyser (Surface Measurement Systems Ltd., London, UK). 
The DVS-1 measures the uptake and loss of water vapour gravimetrically with a mass 
resolution of ± 0.1 µg. The temperature was maintained constant at 25.0 ± 0.1 °C. A mass 
of around 10 mg of powder was loaded into a sample net basket and placed in the system. 
The samples were equilibrated at 0% of relative humidity (RH) until dry, reference mass 
was recorded. The samples were exposed to the following % of RH profile: 0 to 90% in 
10% steps and the same for desorption. At each stage, the sample mass was equilibrated 
(dm/dt ≤ 0.002 mg/min for at least 10 min) before the change of relative humidity. An 
isotherm was calculated from the complete sorption and desorption profile. All DVS 
measurements were performed in duplicate. 
To determine the critical relative humidity of crystallisation of amorphous salts, 
the sample was exposed to the following relative humidity rates: 2.5, 5, 10 and 15% 
RH/h. The critical relative humidity was established as previously described.31,32 Briefly, 
an isotherm was calculated from the complete sorption profile. The amount of sorbed 
water was expressed as a percentage of the dry mass. Crystallisation of the material was 
indicated by the points of inflection. %RH of crystallisation were then plotted versus 
∆RH%/h and linearly extrapolated to 0 ∆RH%/h. 
2.2.11. Solubility and ternary phase diagram studies  
2.2.11.1 Equilibrium solubility studies 
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The solubilities of C, S and salts were determined by adding the solid in 
approximately a 3-fold excess of the amount expected to achieve saturated solubility into 
an Eppendorf tube and adding 2 ml of solvent.7 The Eppendorf vials were then 
hermetically sealed, placed horizontally in a water bath at 25 ºC and shaken at 100 cpm. 
After 24 h the suspensions were filtered through a 0.45 µm PVDF membrane filter7 and 
the content of constituents in the supernatant was determined by HPLC (Section 2.2.13). 
The solubility samples were prepared and tested at least in triplicate. 
2.2.11.2 Dynamic solubility studies 
 Dynamic solubility studies were performed in 20 ml glass vials placed in jacketed 
beakers to control temperature (either 25 or 37 ºC). 5 ml of water was added to each of 
the vials and the solid under investigation was added in approximately a 3-fold excess of 
the expected saturated solubility. Aliquots of the suspension were withdrawn at 
predetermined intervals, filtered through a 0.45 µm PVDF membrane filter7 and the 
content of the drug and the acid in the solution phase was determined by HPLC (Section 
2.2.13). The pH of the aqueous saturated solutions was measured using a Thermo Orion 
420+ pH-meter (Thermo Scientific, Hampshire, UK). The experiments were repeated at 
least in triplicate. The remaining solid material at the end of the solubility studies 
(equilibrium and dynamic) was separated from the liquid by filtration and analysed using 
PXRD.   
2.2.12.1. Construction of a ternary phase diagram 
 A series of mixes of C, S and deionised water containing a varied proportion of 
the components were prepared in 20 ml capped glass vials. The vials were then placed 
horizontally in a water bath at 25 ºC and shaken at 100 cpm. After 24 h the suspensions 
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were filtered through a 0.45 µm PVDF membrane filter and the content of the drug and 
the acid in the solution phase was determined by HPLC (Section 2.2.13). Each 
experiment was repeated at least in duplicate. The remaining solid phase (if present) was 
analysed by PXRD. The equilibrium solubility of C and S was determined as described in 
Section 2.2.11.1. 
2.2.13. High performance liquid chromatography (HPLC) 
The content of ciprofloxacin was determined using the HPLC method described in 
the British Pharmacopeia.33 The content of succinic acid was determined using the 
conditions previously described.7 Briefly, a Shimadzu 10Avp HPLC system (Tokyo, 
Japan) was employed and the separation was done at room temperature. For ciprofloxacin 
the analytical column used was a C18(2) Luna column (250 mm length, internal diameter 
4.6 mm, and particle size 5 µm). The mobile phase was composed of a 2.45 g/l solution 
of phosphoric acid, previously adjusted to pH 3.0 with triethylamine mixed with 
acetonitrile (87:13 v/v). A flow rate of 1.5 ml/min with the UV detection at 278 nm was 
used. For succinic acid the analytical column used was a LiChrosorb RP-10 column (250 
mm length, internal diameter 4 mm, and particle size 10 µm). UV detection was carried 
out at a wavelength of 210 nm and the injection volume was 10 µl. Separation of succinic 
acid was carried out using a gradient method with a flow rate of 1 mL/min. The mobile 
phase consisted of two eluents: (A) phosphoric acid solution (pH 2.1) and (B) methanol 
and a pH=2.1 phosphoric acid solution [20:80 (v/v)]. The following gradient was used: a 
linear gradient from 0% to 50% B over 7 min, and then a linear gradient from 50% to 
100% B over 1 min; this composition was maintained for 7 min. Then, again a linear 
gradient from 100% to 0% B over 10 min was applied, and the final mobile phase 
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composition was continued further for 5 min. Each sample was measured in duplicate and 
each solution was injected in duplicate. 
2.2.14. Scanning Electron Microscopy (SEM)  
SEM analysis was performed using a Zeiss SUPRA Variable Pressure Field 
Emission scanning electron microscope (Jena, Germany). The resolution was 3 nm at 30 
kV, accelerating voltage was 5 kV and the detector used was the secondary electron 
detector. Samples were glued onto aluminium stubs and sputter-coated with gold under 
vacuum prior to analysis. 
2.2.15. Data analysis 
The crystallographic data was analysed in detail using Ortep-334, Platon35 and 
CrystalExplorer (ver.3.0)36 software. The statistical significance of the differences 
between samples was determined using one-way analysis of variance (ANOVA) followed 
by the posthoc Tukey's test using Minitab software. Differences were considered 
significant at p < 0.05. 
 
3. Results and discussion  
 
3.1 Production of crystalline and amorphous salts 
A solid phase, later referred to as CHS-I (ciprofloxacin hemisuccinate (1:1) 
trihydrate), was found to crystallise from a solution of C and S dissolved in the 1:1 molar 
ratio in water. Since succinic acid is a diprotic acid, attempts to obtain a 2:1 ciprofloxacin 
succinate form were made from a solution of C and S dissolved in the 2:1 molar ratio in 
water by evaporative (slow) and cooling (as described in Section 2.2.1.1) crystallisation 
processes. These attempts were unsuccessful and yielded mixtures of CHS-I and another 
solid, later identified as a hydrated form of ciprofloxacin and referred to as C-I. Also 
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reaction crystallisation37 experiments (at room temperature), whereby varying amounts of 
C powders were added to a saturated solution of S in water and water/ethanol mixtures, 
were fruitless. However, when cooling crystallisation from ethanolic solutions was 
devised, it was observed that 50% v/v ethanolic solution containing C and S in the 1:1 
molar ratio resulted in the isolation of a solid, later referred to as CS-I (ciprofloxacin 
succinate (2:1) tetrahydrate). A 0.5 molar excess of S was necessary to prevent C-I 
crystallisation prior to the formation of CS-I. Higher concentrations of ethanol were also 
effective, but resulted in unnecessary dilutions of the crystallisation medium.  It is 
therefore interesting that the 1:1 and 2:1 crystalline salts crystallised from the same 
drug:acid stoichiometry in solution, with only the solvent system being different.  
Anhydrous CHS and CS forms, later referred to as CHS-II and CS-II, were 
obtained by drying CHS-I and CS-I and, in addition, CHS-II was found to form upon 
crystallisation under reduced pressure from a solution of C and S dissolved in the 1:1 
molar ratio in water.  
Spray drying was investigated as a method to generate amorphous forms of 
ciprofloxacin succinate however, due to the very low solubility of the drug in common 
process solvents, this method was employed to process aqueous solutions containing C 
and S in the 1:1 molar ratio only. Samples spray dried from higher feed concentrations 
(2% w/v) were PXRD amorphous, while those dried from lower feed concentrations (1 
and 1.5% w/v) and the sample processed in the closed mode configuration were partially 
crystalline (Fig. 2). The variation in the inlet temperature employed (120-180 °C) did not 
have a noticeable effect on amorphisation of the CS phase, impacting only the content of 
residual water in the spray dried material, which varied from 3.0-0.8% w/w. HPLC 
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showed no chemical degradation of ciprofloxacin on processing. The amorphous sample 
spray dried from a 2% w/v solution of C and S present in the 1:1 molar ratio at an inlet 
temperature of 140 °C (Fig. 2e) was used for further analysis and is referred to as CHS-
III.  
 
Figure 2. PXRD patterns of ciprofloxacin (C) and succinic acid (1:1 molar ratio) spray 
dried at the following conditions (solid concentration, inlet temperature): a) 1.5% w/v, 
160 °C, b) 1.5% w/v, 170 °C, c) 1% w/v, 180 °C, d) 2% w/v, 120 °C, e) 2% w/v, 140 °C 
(CHS-III), f) 2% w/v, 160 °C and g) 2% w/v, 80 °C (closed mode configuration). 
 
Amorphous ciprofloxacin succinate 2:1, later referred to as CS-III, was produced 
by planetary ball milling due to drug solubility limitations. PXRD and DSC were applied 
to determine the milling time sufficient to produce the amorphous phase, which was 6 h 
(Fig. 3). HPLC confirmed that the drug remained intact in all milled samples, thus 
ciprofloxacin did not decompose on processing. Mechanochemistry by neat and solvent-
drop grinding, as one of the screening tools for obtaining crystalline salts, has been 
advocated by Trask et al.38 Various combinations of a counterion and either trimetoprim 
or pyrimethamine were co-ground using a Retsch mixer mill MM200 and the efficiency 
of the process in terms of the successful production of a crystalline salt was reported to be 
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approximately 40% for neat grinding, increasing to 100% for solvent-drop grinding.38 
The mechanical energy and shearing forces generated in the mill allow solid-state 
reactions to be conducted.18 Hasa et al. described the process of mechanochemical salt 
formation of amorphous vinpocetine citrate and vincamine citrate based on dry co-
grinding physical mixtures of the base and the acid containing either crospovidone18 or 
sodium carboxymethyl cellulose.39  
 
Figure 3. PXRD patterns of ciprofloxacin (C) and succinic acid (2:1 molar ratio): a) 
unprocessed, starting mixture (0 h), b) milled for 2 h, c) milled for 4 h and d) milled for 6 
h (CS-III). 
A summary of the various solid-state forms of ciprofloxacin discussed in this 
manuscript is presented in Table 1.  
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Table 1. The solid state forms of ciprofloxacin considered in this manuscript.  
Symbol Name 
Space 
group Cell volume Theoretical 
water content 
[%] 
a α 
b β 
c γ 
*C Ciprofloxacin 
anhydrous40  
P-1 732.431 
0 7.9606(2) 87.868(3) 8.5798(2) 85.153(2) 
10.7739(3) 88.212(1) 
*C-I Ciprofloxacin 1:3.7 
(3:11) hydrate41 
P-1 2751.22 
16.6 13.8921(4) 111.4970(10) 15.0770(5) 105.9840(10) 
16.2208(5) 106.1990(10) 
CHS-I Ciprofloxacin 
hemisuccinate (1:1), 
trihydrate 
P-1 1138.05 
10.7 7.3528(2) 79.038(2) 9.5471(2) 87.943(2) 
16.5419(4) 86.992(2) 
CHS-II Ciprofloxacin 
hemisuccinate (1:1), 
anhydrous 
N/A 
0 
CHS-III Ciprofloxacin succinate 
(1:1), anhydrous, 
amorphous 
N/A 
0 
CS-I Ciprofloxacin succinate 
(2:1), tetrahydrate 
P-1 1978.72 
8.5 9.5788(3) 68.041(3) 13.6952(5) 83.225(3) 
17.0039(5) 73.039(3) 
CS-II Ciprofloxacin succinate 
(2:1), anhydrous 
N/A 0 
CS-III Ciprofloxacin succinate 
(2:1), anhydrous, 
amorphous 
N/A 
0 
* denotes ciprofloxacin forms characterised previously 
3.2. Structural analysis of CHS-I and CS-I 
The unit cell, determined by SCXRD, of ciprofloxacin hemisuccinate (1:1) 
trihydrate (CHS-I) (Table 1, Table SI.1, Fig. SI.1) is packed with two molecules of the 
drug and two molecules of the acid with six molecules of water placed interstitially. The 
aromatic cores of the drug molecules are π-stacked along the crystallographic a-axis at 
3.59 Å distance. The plane of the cyclopropyl ring (C16-C18) of ciprofloxacin is located 
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at an angle of 118.2(1)° to the plane of the quinoline ring (the C1-C5-N1 fragment) and 
the torsion angle for C1-N1-C16-C18 is 43.6(2)°.  
Only one carboxylic group per every molecule of S is deprotonated, which is 
confirmed by the fact that between the O4 or O5 oxygen atoms and the C19 carbon are 
almost the same distances, at 1.269(2) Ǻ and 1.249(2) Ǻ, respectively (Fig. 4a). We 
previously reported full deprotonation of succinic acid in salbutamol succinate, with C-O 
bond distances of 1.274(1) and 1.253(2) Ǻ.7 In the second carboxylic group of S, which is 
protonated, the interatomic distance for O6-C22 is 1.211(2) Ǻ and C22-O7 is 1.324(2) Ǻ.  
The length of the protonated single C-O bond and C=O bond in the carboxylic group of 
adipic acid in the cocrystal of salbutamol hemiadipate salt with adipic acid was 1.322(2) 
and 1.213(2) Ǻ, respectively.7 
 20
 
Figure 4. Ortep view with 50% probability ellipsoids (left) and numbered chemical 
structures (right) of: a) CHS-I and b) CS-I. Water molecules are not included in the 
numbered chemical structures for clarity.  
 
The deprotonated carboxylic group of S forms hydrogen bond with the protonated 
amine group (N3…O5: 2.710(2) Ǻ) as well as with the carboxylic acid (O7…O4: 
2.513(1) Ǻ). Remarkably the protonated oxygen of the acid (O7) acts not only as a H-
bond donor, but also as an acceptor from a water molecule (O10…O7: 2.954(2) Ǻ). The 
water molecules, the protonated amine and the carboxylic acid form a complex three-
dimension hydrogen bond network. There is also an intramolecular H-bond formed 
between O3 of the ketone group and H1o1 of the neighbouring carboxylic group attached 
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to the quinoline ring (1.746(1) Ǻ).  Details of other H-bonds in CHS-I are presented in 
Table SI.2. 
In general, the H-bond network in CHS-I explored by Hirshfeld surface analysis42 
is mainly formed through H-O and H-H interactions which cover 34.0% and 41.1%, 
respectively, of the whole Hirshfeld surface, presented as dnorm reciprocal interactions43 
(Fig. 5).  
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Figure 5. Hirshfeld surface analysis of ciprofloxacin molecules in CHS-I (left column) 
and CS-I (right column, the data for the two crystallographically independent drug 
molecules is presented separately). Top row presents the Hirshfeld surface of 
ciprofloxacin molecule, second row shows the total fingerprint plot of the drug molecule, 
while the third and bottom rows present the % of reciprocal O-H and H-H contacts, 
respectively, in the fingerprint plot of the drug molecule. 
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The unit cell of ciprofloxacin succinate (2:1) tetrahydrate (CS-I) (Table 1, Table 
SI.1) is packed with four molecules of the drug, two disordered molecules of the acid and 
twelve molecules of water (Fig. SI.3). CS-I has a layered structure, whereby the drug 
layers alternate along the b-direction with the layers containing the acid and water 
molecules. π-stacking extends along the crystallographic b-axis at a distance of 3.83 Ǻ. 
The two molecules of drug in CS-I are crystallographically independent (Fig. 4b) and 
later referred to as CPR(1) and CPR(2) based on the label number of the fluorine (F) 
atom, thus Hirshfeld surface analysis was performed for both drug molecules separately. 
The contribution of the H-H contacts in the CPR(1) molecule in comparison to 
ciprofloxacin in CS-I decreased to 33.3% and for the CPR(2) molecule to 37.5% (Fig. 5). 
In contrast, the coverage of the H-O contacts increased to 37.4% and 35.6% for the 
CPR(1) and CPR(2), respectively. The differences are directly related to the 
rearrangement of the hydrogen bonds network and short range contacts as well as the 
differences in the geometry of ciprofloxacin molecules in comparison to CS-I.  
The crystal structure of CS-I presents two cases of disorder. The first is related to 
the molecule of water with O12A and O12B, the second was found in the molecule of 
succinic acid. The disorder in S (Fig. SI.5) comprises two crystallographically 
independent acid molecules (C35-C38) A and B. The torsion angle C35-C36-C37-C38 in 
the molecule A is -173(1)°, while in the molecule B the torsion angle has an opposite sign 
(+173(1)°). This angle is different by 6° when compared to that of the acid molecule in 
CHS-I.  
The extensive disorder in the succinate anion makes it difficult to determine 
whether both carboxylic acid groups in both orientations are fully deprotonated. Large 
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thermal ellipsoids indicate that the positions of the oxygen atoms, especially O9 and O10 
in both orientations, are rather ill-defined, i.e. the carbon-oxygen bond lengths are 
somewhat uncertain. However, in both ciprofloxacin molecules the protons attached to 
the piperazine nitrogens (N3 and N6) were clearly visible in the electron density map. 
This is an indication that N3 and N6 are both fully protonated, so the carboxylate groups 
must all be fully deprotonated. 
In CS-I the protonated amine of CPR-1 forms hydrogen bonds to the succinate 
only (via H3A: N3…O7A: 2.765(5) Ǻ, N3…O7B: 2.705(4) Ǻ; via H3B: N3…O7B: 
2.883(5) Ǻ, N3…O8A: 2.600(3) Ǻ).  Similar intramolecular hydrogen bonds as in CHS-I 
are present (O1…O3: 2.558(2) Ǻ, O4…O6: 2.540(2) Ǻ). The one of CPR-2 forms 
hydrogen bonds to the succinate via H6A (N6…O9B: 2.598(5) Ǻ; N6…O10A:2.846(4) 
Ǻ) and to a water via H6B (N6…O11: 2.763(3) Ǻ). These bonds are stabilised by a 
complex network of hydrogen bonds involving also water molecules as presented in 
Table SI 3.  
Pharmaceutical examples of succinate salts comprising the singly ionised 
succinate moiety include: doxylamine succinate44, sumatriptan succinate45, strychnine 
succinate46, desvenlafaxine succinate47, imiquimod succinate48, in contrast metoprolol 
succinate49 has the counterion double ionised, i.e. both of the carboxylic acid groups are 
deprotonated. Therefore it appears that monodissociated succinic acid prevails in 
pharmaceutical succinate salts and CS-I is a rare example of a salt comprising a fully 
dissociated succinic acid residue. 
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3.3 Physicochemical properties of crystalline salts  
The experimental PXRD pattern of CHS-I (Fig. 6d) was superimposable with that 
calculated from the single crystal analysis (Fig. 6c) and both were different to the 
diffractograms of parent compounds, C and S (Fig. 6a and b). The powder pattern of 
ciprofloxacin starting material used in this study superimposed with the theoretical 
powder pattern of anhydrous ciprofloxacin reported by Fabbiani et al.40 Also, the 
diffractogram of CHS-I was different to that of ciprofloxacin hydrate (Fig. SI.6) observed 
to form in some crystallisation experiments (as described in Section 3.1). This form was 
named C-I and was identified as the 1:3.7 hydrate of the drug.41 The PXRD pattern of 
CS-I (Fig. 6h) was also different to that of C and S.   
 
Figure 6. PXRD analysis of: a) C, b) S, c) simulated pattern of CHS-I based on SCXRD, 
d) CHS-I, e) CHS-II and f) CHS-III, g) simulated pattern of CS-I based on SCXRD, h) 
CS-I,  i) CS-II, j) CS-III.   
 
Anhydrous forms of CHS and CS (CHS-II and CS-II, respectively) had their own, 
distinct diffraction patterns. CHS-II (Fig. 6e) had the characteristic peaks appearing at 
6.41, 11.25, 16.89 and 24.97 2θ degrees, while CS-II (Fig. 6i) presented a PXRD with the 
characteristic peaks at 6.02, 11.56, 11.98, 15.52, 16.30 2θ degrees. 
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Thermal properties and water content of the samples are provided in Table 2. The 
melting point of S was 186.9±0.1 °C (Fig. 7.Ia) while that of C was 265.3±0.6 °C 
(followed by thermal decomposition, Fig. 7.IIb). The endotherm of dehydration of C-I 
had an onset at 91.8±0.1 °C and this process was followed by melting with 
decomposition at 268.4±0.5 °C (Fig. 7.Ic). The first endotherm corresponded to a TGA 
mass loss of 17.3±0.7% (Fig. 7.IIc), which was consistent with the theoretical water 
content of 16.6% (Table 1).  
 
Table 2 Thermal properties and water content of S, C-I, CHS-I and CS-I. N/D – not 
determined. 
Sample Melting point at 10 ºC/min  
(melting point at 500 ºC/min)  
(ºC) 
Enthalpy of 
melting (J/g) 
Water 
content by 
TGA (%) 
Water 
content by 
KF (%) 
S 186.9±0.1 232.2±3.2 N/D N/D 
C-I 268.4±0.5 N/D 17.3±0.7 17.2±0.5 
CHS-I 214.8±0.6 
(243.7±1.1) 
282.5±4.4 12.6±0.8 11.4±0.2 
CS-I 228.1±1.3 
(236.6±1.5) 
181.0±9.4 8.8±0.9 8.1±0.5 
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Figure 7. Thermal analysis: I. DSC thermograms of: a) S, b) C, c) C-I (1:3.7 hydrate), d) 
CHS-I, e) CHS-II, f) CS-I, g) CS-II. II. TGA curves of: a) S, b) C, c) C-I (1:3.7 hydrate), 
d) CHS-I and e) CS-I. 
 
The DSC scan of CHS-I (Fig. 7.Id) presented an evaporation endotherm with ∆H 
of 282.5±4.4 J/g corresponding to a TGA mass loss of 12.6±0.8% (equivalent to 3.6 
molecules of water per 1 molecule of the salt). The water content by KF titrimetry (Table 
2) corresponded to 3.2 molecules of water for 1 molecule of the salt. Therefore the water 
content in CHS-I agrees well with the crystallography data.   
The DSC scan of CS-I (Fig. 7.If) showed a dehydration endotherm with ∆H of 
181.0±9.4 J/g corresponding to a TGA mass loss and KF water content (Table 2) 
equivalent to 4.2 or 3.8 molecules of water per 1 molecule of the salt, respectively. The 
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number of water molecules determined from the crystal structure analysis is in agreement 
with the results of thermal and KF analyses within experimental uncertainty. As CS-I was 
crystallised from 50% v/v ethanolic solution, GC-MS measured that the residual ethanol 
content was 522±88 ppm. This is in agreement with FTIR findings, as the spectrum of 
CS-I (Fig. 8.f) does not suggest the presence of ethanol. The melting of CS-I was 
immediately followed by decomposition (Fig. 7I.f). Thermal analysis showed that the 
melting point of CS-II form was 220.1±0.9 °C, followed by thermal degradation.  
HSDSC was also performed as at a heating rate of 10 ºC/min thermal 
decomposition of the salts was seen. A gradual shift of the melting point of CHS-I and 
CS-I to higher temperatures was observed when the heating rates were ramped from 10 to 
200 ºC/min. A further increase in the heating rates to 500 ºC/min did not impact on the 
onset temperature values considerably. Table 2 shows the melting point values for CHS-I 
and CS-I obtained with the 500 ºC/min rate. HSDSC thermograms for CHS-I and CS-I at 
different scanning rates are presented in Figures SI.7 and SI.8.  
 
Figure 8. FTIR spectra of: I. a) S, b) C, c) CHS-I, d) CHS-II, e) CHS-III, f) CS-I, g) CS-II 
and h) CS-III. 
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The infrared spectrum of C (Fig. 8b) presented characteristic bands at 1617, 1590 
and 1375 cm-1 assigned to the ketone C=O stretch, antisymmetric and symmetric 
vibrations of the carboxylate anion, respectively.50 Hence, the –COOH group of 
ciprofloxacin was deprotonated in C40 in contrast to the crystalline CHS and CS forms 
(Fig. 8), consistent with SC-XRD data. Protonation of the carboxylic group of 
ciprofloxacin in the salts was confirmed by the presence of two strong absorption bands 
at ~1712 cm-1 in CHS-I or ~1724 cm-1 in CS-I and ~1630 cm-1 appearing at similar 
positions when compared to FTIR of ciprofloxacin·HCl (1709 and 1624 cm-1) and 
therefore assigned to the carboxylic and ketone C=O group, respectively.13 The NH group 
of the piperazine ring was protonated in the crystalline salts and represented by the 
occurrence of medium intensity bands in the 2400-2700 cm-1 region.13 Very small 
differences between CHS-I and CS-I were apparent despite the incomplete ionisation of S 
in the latter, and no band was deemed as sufficiently discriminating (Fig. 8).  
Dehydration of CHS-I to CHS-II did not cause major changes in the FTIR spectra, 
although minor differences were noted in the 1300-1450 cm-1 region. In contrast, 
dehydration of CS-I to CS-II resulted in the appearance of new bands e.g. at 1598 cm-1 
and 1424 cm-1 (Fig. 8g). Also, the band at 1384 cm-1 in CS-I was practically invisible in 
CS-II, instead, a strong band at 1339 cm-1 was seen. All these changes indicate 
modification of the neighbourhood around deprotonated –COOH groups of S, but not C. 
3.4 Identification and characterisation of the solid state nature of amorphous salts 
The diffractograms of forms CHS-III and CS-III (Figs. 6f and 6j) displayed 
amorphous halos. The glass transition temperature (Tg) of CHS-III was determined using 
the PerkinElmer StepScanTM method and was 101.0±0.8 °C (∆cp 0.46±0.04 J/g). The 
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amorphous phase was thermally stable up to the onset of crystallisation at 134.2±0.4 °C 
(∆H 46.6±0.3 J/g) followed by melting at 202.0±1.9 °C with thermal degradation (Fig. 9).  
 
Figure 9. DSC analysis of amorphous salts (CHS-III and CS-III) at different heating rates. 
  
The amorphous phase of CS-III was thermally (physically) unstable. The sample 
heated at a 10 °C/min rate up to 80 °C in the DSC instrument showed signs of 
crystallisation to CS-II by PXRD. To avoid a prolonged thermal stress, samples were 
analysed using HyperScanTM at heating rates of 100, 300 and 500 °C/min (Fig. 9). The 
use of a heating rate of 100 °C/min was able to prevent cold crystallisation of the 
amorphous phase. The Tg of CS-III was detected at 81.7±0.6 °C (∆cp ~0.4 J/g·ºC), 
86.2±0.8 °C (∆cp ~0.2 J/g·ºC) and 91.7±1.1 °C (∆cp ~0.5 J/g·ºC) at heating rates of 100, 
300 and 500 °C/min, respectively. A linear relationship between the heating rates and the 
Tgs was found (R2=0.997), and the extrapolated Tg at a 10 °C/min heating rate was 
determined to be 79.29 °C. The Tg was followed by a crystallisation exotherm to CS-II 
with an onset at 111.0±0.3 °C, 117.1±0.5 and 121.6±0.2 °C at a 100, 300 and 500 °C/min 
heating rate, respectively. Melting occurred between ~236 and ~242 °C. Guerrieri et al. 
calculated that the Tg/Tm ratio for procaine salts varied between 0.68-0.82.14 The ratios 
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for CHS-III and CS-III are 0.77 and 0.70, respectively. Ciprofloxacin on its own was, 
unfortunately, not seen to amorphise completely on milling, neither was it possible to use 
spray drying (due to the very low solubility of the drug) or quench cooling (due to the 
thermal decomposition on melting) to produce the disordered form for characterisation.  
 The FTIR patterns of CHS-III and CS-III were essentially superimposable with 
small differences in intensity of some peaks in the fingerprint region (e.g. the band at 
1299 cm-1) due to the different drug to acid composition (Fig. 8). Similarly to the 
crystalline salts, the -NH group of the piperazine ring was protonated and represented by 
the occurrence of medium intensity bands in the 2400-2700 cm-1 region. The carboxylic 
group of the drug was also protonated in CS-III and CHS-III as FTIR showed a strong –
C=O band at ~1700 cm-1. FTIR therefore confirmed the ionic nature and proton transfer 
between the species in the amorphous materials produced either by spray drying or 
milling with no evidence of different amorphous phases formed by ionised and unionised 
drug. The existence of a single Tg for CHS-III and CS-III (Fig. 9) also evidenced the mix 
homogeneity. 
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3.5. Morphology of the salts 
 Scanning electron micrographs of CHS-I, CS-I and spray dried systems 
(amorphous and crystalline) are presented in Fig. 10.  
 
Figure 10. SEM images of: a) and b) CHS-I, c) CS-I, d) CHS-III and e) C and S spray 
dried in the molar ratio of 1:1 (crystalline). 
 
Calculation of crystallite shapes based on the PXRD pattern derived from SCXRD 
(theoretical) and measured (experimental) data indicated that the crystals of CHS-I were 
elongated and formed rectangular prisms (Fig. SI.9). The theoretical crystallite (based on 
the PXRD derived from SCXRD data) consisted of three principal planes: (201), (001) 
and (010), corresponding to the respective Bragg peaks at 24.70, 5.45 and 9.45 2theta 
degrees. A prism of similar shape was determined, based on the experimental data with 
elongation along the a-axis showing the (022), (001) and (10-2) planes corresponding to 
the Bragg peaks at 19.60, 5.40 and 16.30 2theta degrees. This morphology is consistent 
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with that presented in Fig. 10. The crystallite shape calculated for the crystalline spray 
dried sample (sample g) showed appearance of extra planes: (001), (022) and (201) in 
addition to main (10-4) and (211) planes (Fig. SI.9) resulting in adoption of less acicular 
morphology. In this case the growth of each face of the crystal was more uniform, as 
expected when each particle is formed from a single droplet of solution and indicates that 
spray drying may be useful as a crystallisation process to overcome the crystal habit 
issues associated with elongated needles.51  
 The morphology of CS-I based on SCXRD data indicated that prisms were 
formed and were composed of three major planes: (141), (101) and (001) corresponding 
to the Bragg peaks at: 26.50, 11.15 and 5.60 2theta degrees (Fig. SI.10). Calculation of 
the crystal shape from the experimental PXRD pattern indicated that the crystals were 
more elongated along the b-axis in comparison to those estimated from SCXRD, as seen 
in SE micrographs presented in Fig. 10.  
3.6 Solid state stability of crystalline and amorphous salts 
C and C-I were subjected to DVS studies which indicated that, in isothermal 
conditions of the DVS experiment (25 °C), C did not convert to C-I or any other reported 
hydrated form of the drug (Fig. SI.6). C, in the range of 0-90% RH, adsorbed only up to 
0.6% w/w water (Fig. SI.11). The PXRD patterns of C equilibrated to a constant mass in 
0% RH and 90% RH indicated no solid state transformation (Fig. SI.6). In contrast, C-I 
subjected to DVS studies and equilibrated to a constant mass at 0% RH dehydrated, 
losing approximately 17% of the initial mass (m0). This dehydration resulted in a slight 
change in the PXRD pattern of the material, as observed by the disappearance of the peak 
at 6.5 2theta degrees (Fig. SI.6). Rehydration of the material was very rapid and was 
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complete at 20% RH, after which the hydrate remained stable in the range of 20-60% RH. 
A further increase in the relative humidity up to 90% RH resulted in adsorption of an 
additional amount of water to 25% w/w of m0. This second-stage mass increase did not 
result in a change of the PXRD pattern of the material, which may indicate that water was 
adsorbed only on the surface of the powder, or that the C-I crystal lattice has a capacity to 
accommodate additional molecules of interstitial water in the empty voids, as was 
reported previously for hydrates of chlorothiazide sodium and potassium.43,52 Such 
interstitial molecules of water do not change the crystal structure of the hydrate. The 
hydrated C-I form was stable and did not undergo dehydration up to 10% of RH (Figs. 
SI.6 and SI.11).  
  CHS-I subjected to DVS studies dehydrated between 30% and 0% RH losing 
approximately 11% of water (Fig. 11I). This dehydration was related to a change in the 
PXRD pattern assigned to crystallisation of CHS-I into CHS-II (Fig. SI.12). The 
hydration of CHS-II in DVS started slowly, reaching only approximately 5% of m0 up to 
60% of RH and gradually increased to over 10% m0 at 70% RH forming hydrated CHS-I 
(Figs. 11I and SI.12), stable in the range from 90% to 30% of RH. 
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Figure 11. DVS analysis of: I. CHS-I/II (squares) and CS-I/II (circles), II. CHS-III 
(R2=0.997, CRH= 46.7%) and III. CS-III (R2=0.973, CRH= 47.7%). Filled symbols – 
adsorption, empty symbol – desorption, triangles – critical humidity determination data.  
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CS-I subjected to DVS studies was demonstrated to be stable in the range of 30-
90%  RH (Figs. 11I and SI.12). Below 30% RH CS-I dehydrated and crystallised to CS-II 
form (Fig. SI.12). CS-II was much less hygroscopic in comparison to CHS-II, perhaps 
due to a greater amount of the hydrophobic drug. It adsorbed less than 1% of m0 up to 
40% RH (Fig. 11I). Between 40 and 50% RH CS-II gradually sorbed approximately 8% 
of water and crystallised to CS-I (Figs. 11I and SI.12).  
DVS studies on the CHS-III form indicated that the amorphous phase subjected to 
equilibration to a constant mass in the range from 0 to 90% of RH was stable up to 40% 
RH, sorbing approximately 5-6% m0 of water and crystallised in the RH range of 40-50%  
(Figs. 11II and SI.14). The results are consistent with the findings of another DVS 
experiment where crystallisation of the amorphous material was investigated using fixed 
rates of RH changes (2.5 to 15% RH per hour)7 and not the method of equilibration to a 
constant mass. This experiment confirmed that the critical relative humidity of 
crystallisation was 46.7±0.9% (Fig. 11II) and the sample transformed to CHS-I. 
 The mass change magnitude in the DVS studies of CS-III was low and not 
discriminatory enough to record the mass change related to crystallisation of the 
amorphous phase (Fig. 11III). The critical relative humidity of crystallisation was 
determined to be 47.7±0.5% RH in studies which involved subjecting the material to 
changing RH rates (2.5-15% RH per hour) (Fig. 11III). The amorphous phase was stable 
up to 40% RH, but at 40% RH it crystallised forming CS-I, which was stable up to 90% 
RH (Fig. SI.14). In the dehydration cycle the CS-I form was seen to dehydrate to CS-II at 
0% RH.  
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3.7 Solution stability and equilibrium solubility  
CHS-I was stable in water and 50% v/v ethanol/50% v/v water with measured 
total solubilities of 17.4±1.1 and 16.6±2.7 mg/ml, respectively (Table 3). Congruent 
solubility was observed and the solid phase recovered after the experiment was identified 
as the starting material. In pure ethanol the components of CHS-I dissolved incongruently 
and the solid phase was identified as a mix of CHS-I and C. CS-I in water and 50% v/v 
ethanol/50% v/v water was observed to convert to a mix of C-I and CHS-I 
instantaneously (Table 3). CS-I was the stable form in terms of the solid state properties 
when mixed with pure ethanol. 
 
Table 3 Solubility of salts/transformation products in water, ethanol (EtOH) and 50% 
water/50% ethanol v/v mixture (50% EtOH) at 25 ºC. C-ciprofloxacin, S-succinic acid. 
Salt Solvent C concentration 
in liquid phase 
(mg/ml) 
S concentration 
in liquid phase 
(mg/ml) 
C:S 
stoichiometry 
in solution 
Solid state 
phase 
recovered after 
experiment 
CHS-I water 12.8±0.9 4.7±0.2 1:1.02 CHS-I 
CHS-I 50% 
EtOH 
12.1±2.4 4.6±0.3 1:1.08 CHS-I 
CHS-I EtOH 0.01±0.01 2.8±0.1 1:78.5 CHS-I + C 
CS-I water 14.5±0.2 5.4±0.1 1:0.99 CHS-I + C-I 
CS-I 50% 
EtOH 
7.6±0.9 3.2±0.3 1:1.20 CHS-I + C-I 
CS-I EtOH 0.30±0.01 0.14±0.01 1:1.33 CS-I 
 
CS-I was seen to undergo a water-mediated transformation yielding CHS-I and  
C-I when placed in aqueous solutions (Table 3). It was determined that the CS-I form was 
stable for at least 24 h in water/ethanol mixes containing at least 80% v/v ethanol. 
However, as no conversion of CS-I to CHS-I was observed in DVS studies, this water-
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mediated transformation may be water activity dependent, similar to the transition of C to 
C-I.53  
The ternary phase diagram measured at 25 °C for the ciprofloxacin-succinic acid 
system in water is presented in Fig. 12. Six regions were distinguished; these represent a 
single phase of undersaturated solution, so called liquidus (I) and five mixed, solid-liquid 
phases where the solids exist in equilibrium with solutions: ciprofloxacin (as C-I) (II), a 
C-I and CHS-I mix (III), CHS-I (IV), a CHS-I and S mix (V) and S (VI). Two eutectic 
points, E1 (15.2 mg/ml drug and 5.3 mg/ml acid) and E2 (12.7 mg/ml drug and 75.1 
mg/ml acid), are also marked on the phase diagram. Since there is an over 2000-fold 
difference in the aqueous solubilities of the pure components (0.03±0.00 mg/ml for 
ciprofloxacin (as C-I) and 66.8±4.1 mg/ml for S at 25 ºC), one would expect a highly 
unsymmetrical ternary phase diagram. However, as the components are able to ionise and 
impact on each other’s solubility, the liquidus region expanded on the ciprofloxacin-rich 
side of the phase diagram (Fig. 12). The stoichiometric line representing the 1:1 
ciprofloxacin: acid molar composition traverses the phase diagram through the region IV 
only, indicating no drug precipitation during dissolution of CHS-I.  
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Figure 12. The ternary phase diagram for ciprofloxacin-succinic acid-water system at 25 
ºC in mass%. (I) undersaturated solution of ciprofloxacin and succinic acid, (II) 
ciprofloxacin + liquid, (III) ciprofloxacin + CHS-I + liquid, (IV) CHS-I + liquid, (V) 
CHS-I + S +liquid, (VI) S + liquid. The shaded area (VII) with empty squares denotes the 
approximate zone in which the metastable CS-I salt formed from CS-III appears. E1 and 
E2 are the two eutectic points (white circles). The inset on top right is the enlarged upper 
part of the phase diagram.  
 
As CS-I was unstable in water and converted to CHS-I and C-I, its position on the 
phase diagram was marked only tentatively, based on the information collected during 
DVS analysis of CS-III (as described in Section 3.6 above). It can be estimated whether a 
salt formed is thermodynamically stable in a solvent by estimating its free energy (∆Gsalt, 
Eqn.1)54 
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where R is the gas constant, T is the temperature, Ksp is the solubility product of the salt, 
pKC and pKS are the dissociation constants of ciprofloxacin and succinic acid in a given 
solvent, m and n are numbers indicating stoichiometry of the salt while SC and SS are 
molar solubilities of C and S in a given solvent. 
For CS-I to be thermodynamically stable, the following condition has to be 
fulfilled (Eqn.2)54:  
 < 10 ! ∙ "#
$ ∙ "
%         Eqn. 2 
In water at 25 °C the Ksp for CHS-I was 153*10-5 M2, while the pKC and pKS difference is 
1.88, taking the first ionisation constants of the components, giving 401*10-5 M2 for the 
right hand side part of Eqn.2 (Table 4).  Therefore CHS-I is stable in aqueous solutions. 
The Ksp for CS-I was estimated from the dynamic solubility studies and was 44.8*10-5 
M3, while the 10 ! ∙ "#
$ ∙ "
% value was equal to 0.038*10-5 M3 (Table 4), thus 
confirming that CS-I is unstable in water. A summary of the values is presented in Table 
4. 
 
Table 4 Solubility, Ksp and 10pKC-pKS·SCm·SSn values for CHS-I and CS-I in water. Sc and 
Ss – molar solubilities of C and S, respectively, Ksp - the solubility product of the salt, 
pKC and pKS are the dissociation constants of C and S, m and n are numbers indicating 
stoichiometry of the salt.  
Salt SC (M) SS (M) Ksp 10pKC-pKS·SCm·SSn Physical 
stability in 
solvent 
CHS-I 9.36*10-5 0.565 153*10-5 M2 401*10-5  M2 Stable 
CS-I 9.36*10-5 0.565 44.8*10-5 M3 0.038*10-5  M3 Unstable 
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3.8 Dynamic and pH-dependent solubility  
The drug solubility in water at 25 and 37 ºC was low, reaching 0.06±0.01 and 
0.08±0.01 mg/ml, respectively (Figs. 13I and 13II). Dynamic solubility studies of CHS-I 
in water at 25 °C showed that saturation was achieved after 1 hour (Fig. 13I). CHS-I 
dissolved congruently, which was indicated from the 1:1 component stoichiometry in 
solution. CHS-III reached saturation quicker than CHS-I, after 1 minute. The drug: acid 
solution stoichiometry was 1:0.97 and the solid phase recovered after the study was  
CHS-I. CS-I in water at 25 °C showed a peak of drug supersaturation (27.5±0.7 mg/ml) at 
60 seconds and this ciprofloxacin solution supersaturation lasted for over 10 minutes, 
after which the drug concentration was comparable to that of CHS-III (Fig. 13I). A rapid 
change in the drug:acid solution stoichiometry was seen as initially the ratio was 1:0.63, 
indicating an excess of ciprofloxacin in solution, then at 10 minutes it was 1:0.97, the 
same as that of CHS-III. The excess solid recovered from the solubility study suspension 
was a C-I and CHS-I mix.  
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Figure 13. Dynamic solubility studies in water at 25 and 37 ºC. Presented are average 
values (n=3) and standard deviations as well as solution pH values at 60 minutes of the 
experiment. 
 
High and sustainable ciprofloxacin levels in solution were attained with CS-III. 
The solution drug:acid stoichiometry ratios measured over time were anomalous since, at 
the first time point, after 10 seconds, the drug: acid ratio was 1:0.89, then rapidly 
decreased to 1:0.56 at 30 seconds and then gradually increased to 1:0.90 at 60 minutes of 
the experiment. These changes may indicate complex solid-state transformations of  
CS-III mediated by the presence of water with the possibility of a liquid-liquid phase 
separation as seen for other poorly soluble drugs55. Similarly to CS-I, CS-III in water also 
converted to a mixture of C-I and CHS-I. A physical mix comprising CHS-I and C-I in a 
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1:1 molar ratio was also investigated to assess the impact of C-I excess on the salt 
solubility, however this sample gave the lowest drug concentrations in solution (Fig. 13I). 
Also, the physical mix composed of S and C in a 1:1 molar ratio was not superior to CS-I 
and CS-III in terms of drug concentrations measured. The final pH of the saturated 
solutions formed by the above samples varied between 4.65-4.75 with no obvious trends 
which would explain the increased drug concentration in solution as a result of pH 
changes. 
The rank order of drug solution concentrations achieved from the various systems 
at 60 minutes of studies in water at 37 °C was different to that at 25 °C (Fig. 13II). The 
lowest ciprofloxacin concentrations were obtained from CHS-III and the S/C physical 
mix, then CHS-I and CS-I followed by the CHS-I/C-I physical mix. Again, the greatest 
drug concentrations were achieved with CS-III (Fig. 13II). CS-I showed a drug 
supersaturation (38.3±0.3 mg/ml) at 10 seconds, but lasting only up to 5 minutes, then the 
drug concentration was comparable to that of the CHS-I/C-I physical mix. A small 
supersaturation peak was seen for the S/C physical mix. Similarly to the experiments 
performed in water at 25 °C, the low or high drug solution concentrations could be 
related to the ratios of molar concentrations of the drug to the acid.  
Solubility studies of CHS-I at a pH of 2 and 3.4, where the pH was adjusted using 
HCl as this ion is present in the gastric fluid, revealed that at the equilibrium (attained 
after approximately 1 hour) the precipitate/excess salt was made of CHS-I and a 
hydrochloride salt of ciprofloxacin. The pH-solubility profile of different salts of 
ciprofloxacin is presented in Fig. SI.17 and suggests that CHS-I may be the better soluble 
form at higher pH values. 
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4. Conclusions  
In this work we have successfully synthesised crystalline salts of ciprofloxacin 
succinate, each with a distinct drug/acid stoichiometry and hydration level. The drug was 
seen to amorphise when co-processed with succinic acid by spray drying or milling 
yielding amorphous and anhydrous salts with 1:1 or 2:1 stoichiometry, equivalent to the 
crystalline salts. The proton transfer in both amorphous forms was confirmed by FTIR. 
The crystalline salts, CHS-I and CS-I, had similar melting points at ~215 and ~228 °C, 
respectively, while the glass transition temperature of CHS-III and CS-III was ~101 and 
~79 °C, respectively.  
The ternary phase diagram was demonstrated to be useful in predicting the 
stability of the crystalline salts in water. Moreover DVS studies complemented these 
experiments providing information on stability of the various phases at low moisture 
contents.  
The metastable nature of the crystalline ciprofloxacin succinate 2:1 in water led to 
the attainment of transient drug supersaturation, peaking at 38.3±0.2 mg/ml in water at 37 
ºC. The amorphous 2:1 salt was superior to the systems investigated in terms of the 
solubility behaviour presenting long-lasting drug supersaturation concentrations, 
characteristic of so-called “spring”, but not “spring-parachute” systems.56 Further studies 
are required to reveal the biopharmaceutical potential of such supersaturating systems, 
especially in the context of formulation development.  
Supporting information 
Supporting Information (SI) material containing additional figures or tables 
referred to across the manuscript as SI.X are available free of charge via Internet at 
http://pubs.acs.org. 
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The Crystallographic information files (CIFs) of CHS-I and CS-I reported in this work 
(pal02 and pal04 - CCDC 870866 & 870867) are available free of charge from 
Cambridge Crystallographic Data Centre (CCDC) via: www.ccdc.cam.ac.uk. 
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